VERAXA Biotech (NASDAQ: VRXA) is broadening its use of human-relevant preclinical testing methods across its antibody-based cancer drug development programs, a strategic shift that could enhance the predictive value of early research while cutting reliance on animal models. The company is implementing New Approach Methodologies (NAMs), including three-dimensional tumor spheroid models and patient-derived tumor models, to support its BiTAC(R) T-cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates, according to a recent announcement.
The implications for drug development are significant. Traditional animal studies often fail to accurately predict human responses, leading to high failure rates in clinical trials. By adopting NAMs, VERAXA aims to generate data that better reflects human biology, potentially accelerating the path to effective therapies. The company reported that its lead BiTAC T-cell engager demonstrated selective, potent T-cell-mediated tumor-cell killing across 10 patient-derived non-small cell lung cancer models, while relevant controls showed minimal activity. This ex vivo study required approximately 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies, underscoring the efficiency and ethical advantages of the approach.
The findings also support VERAXA’s dual-targeting approach, which is designed to direct immune activity toward cancer cells expressing two selected targets. This precision could reduce off-tumor effects and improve safety profiles. For investors, the move signals a commitment to innovation that may streamline development timelines and reduce costs associated with animal testing, a growing consideration for both regulators and the public. As the company advances its pipeline of ADCs and proprietary BiTAC formats into clinical development, the use of human-relevant models could become a competitive differentiator.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. For regular updates about VERAXA Biotech, visit https://investors.veraxa.com. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
The announcement was disseminated through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides access to a vast network of wire solutions, including editorial syndication to 5,000+ outlets, social media distribution, and corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
